---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-23-000043"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T02:18:10.379928+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q1 GAAP net loss $76.6M; INGREZZA sales $410M (+36% YoY)

## Summary
- INGREZZA net sales $410M, up 36% YoY; guidance reiterated at $1.67-1.77B for FY2023.
- GAAP net loss $76.6M ($0.79 loss per share) vs $13.9M income in Q1 2022.
- Non-GAAP net loss $49.5M ($0.51 loss per share) vs $29.7M income in prior year.
- Recorded $143.9M acquired IPR&D expense for Voyager gene therapy collaboration.
- Valbenazine PDUFA for Huntington chorea set for Aug 20, 2023; top-line data from crinecerfont expected early Q4.

## SEC filing metadata
- accession: 0000914475-23-000043
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447523000043/0000914475-23-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447523000043/nbix-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-23-000043
- JSON: https://secwatch.observer/filing/0000914475-23-000043.json
- Plain text: https://secwatch.observer/filing/0000914475-23-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.